Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)
(2025) In World Allergy Organization Journal 18(7).- Abstract
- Background: Asthma characterization using blood eosinophil count (BEC) (among other biomarkers and clinical indices) is recommended in severe asthma (SA), but the masking effect of oral corticosteroids (OCS), makes this challenging. Aim: Our aim was to explore the effect of OCS use (both intermittent [iOCS] and long-term [LTOCS]) prior to biologic initiation on SA phenotype and biomarker profile in real-life and to characterize the burden of SA among patients prescribed LTOCS by biomarker profile. Methods: This was a registry-based cohort study, including data from 23 countries collected between 2003 and 2023 and shared with the Internatonal Severe Asthma Registry (ISAR). Patients with SA were categorized into 3 cohorts, those with: (i) no... (More)
- Background: Asthma characterization using blood eosinophil count (BEC) (among other biomarkers and clinical indices) is recommended in severe asthma (SA), but the masking effect of oral corticosteroids (OCS), makes this challenging. Aim: Our aim was to explore the effect of OCS use (both intermittent [iOCS] and long-term [LTOCS]) prior to biologic initiation on SA phenotype and biomarker profile in real-life and to characterize the burden of SA among patients prescribed LTOCS by biomarker profile. Methods: This was a registry-based cohort study, including data from 23 countries collected between 2003 and 2023 and shared with the Internatonal Severe Asthma Registry (ISAR). Patients with SA were categorized into 3 cohorts, those with: (i) no prescription for OCS, (ii) prescription(s) for iOCS (ie, ≤90 days in previous 12-months, usually short courses for exacerbations), and (iii) prescriptions for LTOCS (ie, >90 days in previous 12-months). Biomarker distribution (ie, BEC, fractional exhaled nitric oxide [FeNO], and total Immunoglobulin E [IgE]) were quantified in the year prior to biologic initiation in patients with SA according to OCS prescription pattern. Phenotypes were characterized for those prescribed LTOCS according to BEC cut-off ( (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/ee67f079-190c-45f4-8f78-249ef5992faa
- author
- Schleich, F. ; Bjermer, L. LU and Price, D.B.
- author collaboration
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- BEC, Blood eosinophil count, FeNO, Fractional exhaled nitric oxide, IgE, Immunoglobulin E, Intermittent, Long-term, biological marker, corticosteroid, immunoglobulin E, adult, aged, airway obstruction, alternative medicine, Article, clinical feature, cohort analysis, comparative study, controlled study, disease burden, disease classification, disease exacerbation, disease registry, drug dose regimen, drug effect, drug intermittent therapy, drug use, eosinophil count, evidence based practice, female, fractional exhaled nitric oxide, health care utilization, human, human cell, long term care, major clinical study, male, medical decision making, middle aged, patient coding, phenotype, prescription, severe asthma, treatment duration, very elderly
- in
- World Allergy Organization Journal
- volume
- 18
- issue
- 7
- article number
- 101066
- publisher
- Elsevier
- external identifiers
-
- scopus:105007066891
- pmid:40524942
- ISSN
- 1939-4551
- DOI
- 10.1016/j.waojou.2025.101066
- language
- English
- LU publication?
- yes
- id
- ee67f079-190c-45f4-8f78-249ef5992faa
- date added to LUP
- 2026-03-10 12:53:33
- date last changed
- 2026-03-11 03:00:07
@article{ee67f079-190c-45f4-8f78-249ef5992faa,
abstract = {{Background: Asthma characterization using blood eosinophil count (BEC) (among other biomarkers and clinical indices) is recommended in severe asthma (SA), but the masking effect of oral corticosteroids (OCS), makes this challenging. Aim: Our aim was to explore the effect of OCS use (both intermittent [iOCS] and long-term [LTOCS]) prior to biologic initiation on SA phenotype and biomarker profile in real-life and to characterize the burden of SA among patients prescribed LTOCS by biomarker profile. Methods: This was a registry-based cohort study, including data from 23 countries collected between 2003 and 2023 and shared with the Internatonal Severe Asthma Registry (ISAR). Patients with SA were categorized into 3 cohorts, those with: (i) no prescription for OCS, (ii) prescription(s) for iOCS (ie, ≤90 days in previous 12-months, usually short courses for exacerbations), and (iii) prescriptions for LTOCS (ie, >90 days in previous 12-months). Biomarker distribution (ie, BEC, fractional exhaled nitric oxide [FeNO], and total Immunoglobulin E [IgE]) were quantified in the year prior to biologic initiation in patients with SA according to OCS prescription pattern. Phenotypes were characterized for those prescribed LTOCS according to BEC cut-off (}},
author = {{Schleich, F. and Bjermer, L. and Price, D.B.}},
issn = {{1939-4551}},
keywords = {{BEC; Blood eosinophil count; FeNO; Fractional exhaled nitric oxide; IgE; Immunoglobulin E; Intermittent; Long-term; biological marker; corticosteroid; immunoglobulin E; adult; aged; airway obstruction; alternative medicine; Article; clinical feature; cohort analysis; comparative study; controlled study; disease burden; disease classification; disease exacerbation; disease registry; drug dose regimen; drug effect; drug intermittent therapy; drug use; eosinophil count; evidence based practice; female; fractional exhaled nitric oxide; health care utilization; human; human cell; long term care; major clinical study; male; medical decision making; middle aged; patient coding; phenotype; prescription; severe asthma; treatment duration; very elderly}},
language = {{eng}},
number = {{7}},
publisher = {{Elsevier}},
series = {{World Allergy Organization Journal}},
title = {{Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR)}},
url = {{http://dx.doi.org/10.1016/j.waojou.2025.101066}},
doi = {{10.1016/j.waojou.2025.101066}},
volume = {{18}},
year = {{2025}},
}